KR20250109791A - 담즙산 유도체 제조를 위한 방법 및 중간체 - Google Patents

담즙산 유도체 제조를 위한 방법 및 중간체

Info

Publication number
KR20250109791A
KR20250109791A KR1020257022279A KR20257022279A KR20250109791A KR 20250109791 A KR20250109791 A KR 20250109791A KR 1020257022279 A KR1020257022279 A KR 1020257022279A KR 20257022279 A KR20257022279 A KR 20257022279A KR 20250109791 A KR20250109791 A KR 20250109791A
Authority
KR
South Korea
Prior art keywords
compound
formula
chemical formula
acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257022279A
Other languages
English (en)
Korean (ko)
Inventor
로베르토 펠리치아리
안티모 지오이엘로
가브리엘 갈빈
로날드 디. 루이스
매튜 야닉
명구 김
프레드 로날드 루싱크
바르티안 코닝
토마스 헨젤
Original Assignee
인터셉트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셉트 파마슈티컬즈, 인크. filed Critical 인터셉트 파마슈티컬즈, 인크.
Publication of KR20250109791A publication Critical patent/KR20250109791A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020257022279A 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체 Pending KR20250109791A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762523937P 2017-06-23 2017-06-23
US62/523,937 2017-06-23
KR1020207002009A KR102831293B1 (ko) 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체
PCT/US2018/039148 WO2018237350A1 (en) 2017-06-23 2018-06-22 METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002009A Division KR102831293B1 (ko) 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체

Publications (1)

Publication Number Publication Date
KR20250109791A true KR20250109791A (ko) 2025-07-17

Family

ID=64691408

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257022279A Pending KR20250109791A (ko) 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체
KR1020207002009A Active KR102831293B1 (ko) 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002009A Active KR102831293B1 (ko) 2017-06-23 2018-06-22 담즙산 유도체 제조를 위한 방법 및 중간체

Country Status (10)

Country Link
US (2) US11066437B2 (https=)
EP (1) EP3642217A4 (https=)
JP (1) JP7224307B2 (https=)
KR (2) KR20250109791A (https=)
CN (1) CN110945006A (https=)
AU (1) AU2018288883B2 (https=)
BR (1) BR112019027458A2 (https=)
CA (1) CA3067219A1 (https=)
IL (3) IL326587A (https=)
WO (1) WO2018237350A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
US20230128984A1 (en) * 2020-01-31 2023-04-27 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (ibd)
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US12215127B2 (en) 2020-04-17 2025-02-04 Cornell University Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN112795615A (zh) * 2021-02-03 2021-05-14 湖南醇康医药科技有限公司 一种诱变菌种以及微生物发酵制备熊去氧胆酸的方法
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN114045239B (zh) * 2021-11-08 2023-09-29 浙江树人学院（浙江树人大学） 具有二甲基乙酰胺降解能力的泛养副球菌ybh-7及应用
US20250288600A1 (en) * 2022-04-21 2025-09-18 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024163640A2 (en) * 2023-02-01 2024-08-08 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US2554882A (en) * 1943-02-04 1951-05-29 Reichstein Tadeus 3-hydroxy-11-ketoetiocholanic acid and its esters
US3277121A (en) * 1964-05-04 1966-10-04 Canada Packers Ltd Conversion of delta11-steroids to 11-oxygenated steroids
DE3040634A1 (de) * 1980-10-29 1982-05-27 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 3 (alpha) -hydroxy-5- (beta) -pregnan-11,20-dion
JPS58155098A (ja) * 1982-03-09 1983-09-14 Yakult Honsha Co Ltd 微生物によるウルソデオキシコ−ル酸の製造法
WO1990009394A2 (en) * 1989-02-07 1990-08-23 The Upjohn Company Dehalogenation of organic compounds using tin or lead
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN108137643A (zh) * 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
CN107973834A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 作为fxr/tgr5调节剂的胆酸衍生物
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof

Also Published As

Publication number Publication date
AU2018288883B2 (en) 2022-06-02
CA3067219A1 (en) 2018-12-27
US20180371009A1 (en) 2018-12-27
US11066437B2 (en) 2021-07-20
IL304455B1 (en) 2026-03-01
AU2018288883A1 (en) 2020-01-16
CN110945006A (zh) 2020-03-31
EP3642217A4 (en) 2021-06-16
IL304455A (en) 2023-09-01
IL271343B2 (en) 2023-12-01
US20220127302A1 (en) 2022-04-28
JP2020525426A (ja) 2020-08-27
IL326587A (en) 2026-04-01
KR20200020877A (ko) 2020-02-26
WO2018237350A1 (en) 2018-12-27
KR102831293B1 (ko) 2025-07-08
JP7224307B2 (ja) 2023-02-17
IL271343B1 (en) 2023-08-01
IL271343A (en) 2020-01-30
BR112019027458A2 (pt) 2020-07-07
EP3642217A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
KR102831293B1 (ko) 담즙산 유도체 제조를 위한 방법 및 중간체
US12291549B2 (en) Farnesoid X receptor modulators
CN110003301B (zh) 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
AU2016297821B2 (en) Methods for preparation of bile acids and derivatives thereof
JP2018528230A (ja) 胆汁酸誘導体の調製のための方法および中間体
ES2280739T3 (es) Procedimiento para preparar 5-androstenos sustituidos en c-7.
US20130102580A1 (en) Compositions and methods related to deoxycholic acid and its polymorphs
WO2024163640A2 (en) Methods and intermediates for the preparation of bile acid derivatives
WO2019020067A1 (zh) 甾体类衍生物fxr激动剂的制备方法
WO2023288123A1 (en) Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN101676296A (zh) 制备21位羧酸酯甾体化合物的方法及使用该方法制备的甾体化合物
CN101880309A (zh) 一种天然产物23-羟基白桦酸的半合成方法
HK1251216A1 (en) Methods for preparation of bile acids and derivatives thereof

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)